Full-Time

Vice President

Analytical Development

Updated on 4/30/2024

Verve Therapeutics

Verve Therapeutics

201-500 employees

Develops gene editing medicines for cardiovascular disease

Biotechnology

Compensation Overview

$288,000 - $360,000Annually

Senior, Expert

Cambridge, MA, USA

Required Skills
Communications
Requirements
  • Demonstrated history of effective leadership
  • Experience with method development, qualification, and validation for clinical and commercial products
  • Experience in characterization of advanced therapies, ideally gene editing, RNA, and/or LNP products
  • Experience with international regulatory interactions
  • Excellent written and verbal communication skills
  • BS in sciences, analytical chemistry, biochemistry, pharmacy, or related area, advanced degree preferred with 15+ years of progressive leadership experience
Responsibilities
  • Lead and grow a team of analytical scientists and research associates responsible for developing and optimizing analytical assays
  • Test non-GMP samples to support development studies
  • Collaborate with R&D and Quality Control teams to transfer and qualify methods
  • Enhance product and process understanding by characterizing impurities and defining CQAs
  • Improve lab management and operations including lab safety, budget, quality systems, data reporting/management, productivity initiatives
  • Write and review regulatory filings and briefing books
  • Promote a culture of continuous improvement and collaboration

Verve Therapeutics focuses on the development of single-course gene editing treatments aimed at addressing cardiovascular diseases by lowering LDL cholesterol and triglyceride levels. The company's lead program targets a critical and potentially fatal genetic condition, positioning it at the forefront of genetic medicine in heart disease management. This emphasis on specialized and life-altering therapies makes it an excellent workplace for those passionate about contributing to significant advancements in medical science and patient care.

Company Stage

IPO

Total Funding

$419.3M

Headquarters

Boston, Massachusetts

Founded

2018

Growth & Insights
Headcount

6 month growth

3%

1 year growth

10%

2 year growth

84%